GoAI
Get started
Fuji Pharma Co., Ltd. logo

Fuji Pharma Co., Ltd.

4554.T

JPXHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Latest quote

¥1,838

−¥9.00 · -0.49%

Aug 24, 3:30 PM JST

4554.T company overview

Regular session · JST · Market data may be delayed.

Company profile

Company website

Fuji Pharma Co., Ltd. is a pharmaceutical company that operates globally, focusing on the complete spectrum of drug development, from initial research and discovery through manufacturing and commercialization. Its comprehensive product line includes various medical solutions such as injectable medications, oral therapeutics, topical treatments, and a range of diagnostic tools. Beyond its core pharmaceutical offerings, Fuji Pharma also specializes in women's healthcare products, advanced in vitro diagnostic technologies, and acute medical intervention solutions. The company further contributes by disseminating valuable pharmaceutical and general health information. Founded in 1965, Fuji Pharma Co., Ltd. has its corporate headquarters located in Tokyo, Japan.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
JP
CEO
Shuhei Morita
Listed since
Feb 22, 2010
Employees
1,760

Market position

Day range

Current ¥1,838

52-week range

Current ¥1,838

Open
¥1,856
Previous close
¥1,847
Volume
53.8K
0.41× average
Average volume
129.87K
Average daily volume
Market cap
48.01B JPY
Beta
0.33
Market reference 1
50-day average
¥1,973.8
-6.88% below average
200-day average
¥2,056.86
-10.64% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
61.42B JPY
P/E (TTM)
15.45×
P/B (TTM)
0.93×
P/S (TTM)
0.8×
EV / EBITDA
6.86×
Earnings yield
7.95%
Free cash flow yield
10.13%
Dividend yield
2.64%

Profitability & efficiency

Gross margin
39.39%
Operating margin
11.67%
Net margin
4.97%
Return on equity
6.40%
Return on assets
3.20%
Return on invested capital
4.65%

Financial health

Debt / equity
0.56×
Current ratio
1.55×
Altman Z-score
2.26
Piotroski F-score
7 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends45%31%17%2%Gross margin, FY2021: 41.59%Gross margin, FY2022: 38.44%Gross margin, FY2023: 37.60%Gross margin, FY2024: 35.79%Gross margin, FY2025: 37.33%Operating margin, FY2021: 9.85%Operating margin, FY2022: 10.66%Operating margin, FY2023: 9.44%Operating margin, FY2024: 8.41%Operating margin, FY2025: 9.66%Net margin, FY2021: 7.16%Net margin, FY2022: 7.61%Net margin, FY2023: 8.40%Net margin, FY2024: 13.32%Net margin, FY2025: 5.81%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 41.59%. Gross margin FY2022 38.44%. Gross margin FY2023 37.60%. Gross margin FY2024 35.79%. Gross margin FY2025 37.33%. Operating margin FY2021 9.85%. Operating margin FY2022 10.66%. Operating margin FY2023 9.44%. Operating margin FY2024 8.41%. Operating margin FY2025 9.66%. Net margin FY2021 7.16%. Net margin FY2022 7.61%. Net margin FY2023 8.40%. Net margin FY2024 13.32%. Net margin FY2025 5.81%.

Income trends

Revenue

51.68B JPY+12.01%

Operating income

4.99B JPY+28.58%

Net income

3B JPY-51.20%
Income trends across reported periods56.6B JPY36.9B JPY17.21B JPY−2.49B JPYRevenue, FY2021: 33.99B JPYRevenue, FY2022: 35.43B JPYRevenue, FY2023: 40.89B JPYRevenue, FY2024: 46.14B JPYRevenue, FY2025: 51.68B JPYOperating income, FY2021: 3.35B JPYOperating income, FY2022: 3.78B JPYOperating income, FY2023: 3.86B JPYOperating income, FY2024: 3.88B JPYOperating income, FY2025: 4.99B JPYNet income, FY2021: 2.43B JPYNet income, FY2022: 2.7B JPYNet income, FY2023: 3.44B JPYNet income, FY2024: 6.15B JPYNet income, FY2025: 3B JPYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 33.99B JPY. Revenue FY2022 35.43B JPY. Revenue FY2023 40.89B JPY. Revenue FY2024 46.14B JPY. Revenue FY2025 51.68B JPY. Operating income FY2021 3.35B JPY. Operating income FY2022 3.78B JPY. Operating income FY2023 3.86B JPY. Operating income FY2024 3.88B JPY. Operating income FY2025 4.99B JPY. Net income FY2021 2.43B JPY. Net income FY2022 2.7B JPY. Net income FY2023 3.44B JPY. Net income FY2024 6.15B JPY. Net income FY2025 3B JPY.
Metric (JPY)FY2025FY2024FY2023FY2022FY2021
Revenue51.68B JPY46.14B JPY40.89B JPY35.43B JPY33.99B JPY
Cost of goods sold32.39B JPY29.63B JPY25.52B JPY21.81B JPY19.86B JPY
Gross profit19.29B JPY16.51B JPY15.37B JPY13.62B JPY14.14B JPY
Research and development3.34B JPY3.4B JPY3.18B JPY2.49B JPY2.45B JPY
Selling, general, and administrative10.96B JPY9.23B JPY8.33B JPY7.36B JPY8.34B JPY
Operating expenses14.3B JPY12.63B JPY11.52B JPY9.84B JPY10.79B JPY
Interest expense330M JPY196M JPY121M JPY77M JPY53M JPY
Depreciation and amortization3.97B JPY3.68B JPY3.02B JPY2.75B JPY2.11B JPY
Operating income4.99B JPY3.88B JPY3.86B JPY3.78B JPY3.35B JPY
Net income3B JPY6.15B JPY3.44B JPY2.7B JPY2.43B JPY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
43.36

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates53.9439.3924.8510.3Q4 '24Q1 '25Q2 '25Q3 '25Q3 '25Q1 '26Q2 '26Q3 '26
Q4 2024, reported Nov 12, 2024: actual 50.84, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Feb 6, 2025: actual 40.74, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 8, 2025: actual 12.12, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 6, 2025: actual 22.23, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Sep 30, 2025: actual 47.92, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 5, 2026: actual 13.28, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 12, 2026: actual 15.47, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 6, 2026: actual 43.36, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates18.2B15.6B13B10.4BQ1 '25BeatQ2 '25MissQ3 '25MissQ3 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 6, 2025: actual 13B JPY, estimate 11.19B JPY, surprise +16.14%, Beat. Q2 2025, reported May 8, 2025: actual 11.1B JPY, estimate 13.3B JPY, surprise -16.58%, Miss. Q3 2025, reported Aug 6, 2025: actual 12.86B JPY, estimate 14.4B JPY, surprise -10.70%, Miss. Q3 2025, reported Sep 30, 2025: actual 14.72B JPY, estimate 14.55B JPY, surprise +1.22%, Beat. Q1 2026, reported Feb 5, 2026: actual 15.9B JPY, estimate 14.4B JPY, surprise +10.40%, Beat. Q2 2026, reported May 12, 2026: actual 13.82B JPY, estimate 13.5B JPY, surprise +2.34%, Beat. Q3 2026, reported Aug 6, 2026: actual 15.67B JPY, estimate 15.78B JPY, surprise -0.75%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate 17.5B JPY, surprise —, Comparison unavailable.

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

¥45.50

2025 complete year+56.9% since 2021

2026 partial: ¥23.00

* Partial calendar year in the available dividend history.

Corporate action history

DividendUpcoming

Ex-dividend Sep 29, 2026

¥26.00

Semi-Annual

Record Sep 30, 2026 · Payment Sep 29, 2026

Dividend

Ex-dividend Mar 30, 2026

¥23.00

Annual

Record Mar 31, 2026 · Payment Jun 1, 2026

Dividend

Ex-dividend Sep 29, 2025

¥25.50

Special

Record Sep 30, 2025 · Payment Dec 22, 2025

Dividend

Ex-dividend Mar 28, 2025

¥20.00

Semi-Annual

Record Mar 31, 2025 · Payment Jun 2, 2025

Dividend

Ex-dividend Sep 27, 2024

¥22.50

Semi-Annual

Record Sep 30, 2024 · Payment Dec 23, 2024

Dividend

Ex-dividend Mar 28, 2024

¥20.00

Semi-Annual

Record Mar 31, 2024 · Payment Jun 3, 2024

4554.T peers

Chugai Pharmaceutical Co., Ltd. logo

4519.T

Chugai Pharmaceutical Co., Ltd.

¥6,973

-0.54%

Takeda Pharmaceutical Company Limited logo

4502.T

Takeda Pharmaceutical Company Limited

¥5,815

+0.88%

HOYA Corporation logo

7741.T

HOYA Corporation

¥24,975

+0.32%

Otsuka Holdings Co., Ltd. logo

4578.T

Otsuka Holdings Co., Ltd.

¥12,205

+0.08%

Daiichi Sankyo Company, Limited logo

4568.T

Daiichi Sankyo Company, Limited

¥2,862

+1.01%

Astellas Pharma Inc. logo

4503.T

Astellas Pharma Inc.

¥2,406

+0.80%

ETFs holding 4554.T

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Core TOPIX ETF logoiShares Core TOPIX ETF1475.T
Market value
72.77M
Weight
0.00%
AUM
2.89T JPY
Expense ratio
0.05%
Price / 1D
¥417.7—
Avantis International Small Cap Value ETF logoAvantis International Small Cap Value ETFAVDV
Market value
2.92M
Weight
0.01%
AUM
20.24B USD
Expense ratio
0.36%
Price / 1D
$111.95—
Vanguard Total International Stock ETF logoVanguard Total International Stock ETFVXUS
Market value
2.31M
Weight
0.00%
AUM
646.2B USD
Expense ratio
0.05%
Price / 1D
$87.71—
Vanguard FTSE Developed Markets ETF logoVanguard FTSE Developed Markets ETFVEA
Market value
1.5M
Weight
0.00%
AUM
315B USD
Expense ratio
0.03%
Price / 1D
$73.42—
Dimensional - International Small Cap Value ETF logoDimensional - International Small Cap Value ETFDISV
Market value
1.46M
Weight
0.03%
AUM
5.23B USD
Expense ratio
0.42%
Price / 1D
$44.49—
Vanguard FTSE All-World ex-US Small-Cap ETF logoVanguard FTSE All-World ex-US Small-Cap ETFVSS
Market value
543.76K
Weight
0.00%
AUM
13.6B USD
Expense ratio
0.06%
Price / 1D
$160.06—
Dimensional - International Small Cap ETF logoDimensional - International Small Cap ETFDFIS
Market value
376.45K
Weight
0.01%
AUM
5.91B USD
Expense ratio
0.39%
Price / 1D
$37.545—
Schwab International Small-Cap Equity ETF logoSchwab International Small-Cap Equity ETFSCHC
Market value
359.82K
Weight
0.01%
AUM
5.73B USD
Expense ratio
0.06%
Price / 1D
$51.25—

Continue in GoAI

Research 4554.T

research.disclaimer